Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 864-872

  Butterfield, Jill M ^a   Mueller, Bruce A ^b   Patel, Nimish ^a   Cardone, Katie E ^a   Grabe, Darren W ^a   Salama, Noha N ^c,d   Lodise, Thomas P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CREATINE KINASE; DAPTOMYCIN; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; RENAL DIALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84872868885     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02000-12     Document Type: Article

References (26)

1. United States Renal Data System. 2010. USRDS 2008 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Allon M. 2004. Dialysis catheter-related bacteremia: Treatment and prophylaxis. Am. J. Kidney Dis. 44:779-791.
3. Verdalles U, Abad S, Aragoncillo I, Villaverde M, Jofre R, Verde E, Vega A, Lopez-Gomez JM. 2010. Factors predicting mortality in elderly patients on dialysis. Nephron Clin. Pract 115:c28-c34.
4. Centers for Disease Control and Prevention. 2007. Invasive methicillinresistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 56:197-199.
5. Parker MG, Doebbeling BN. 2012. The challenge of methicillin-resistant Staphylococcus aureus prevention in hemodialysis therapy. Semin. Dial. 25:42-49.
6. Bloembergen WE, Port FK. 1996. Epidemiological perspective on infections in chronic dialysis patients. Adv. Renal Replace. Ther. 3:201-207.
7. Cubist Pharmaceuticals. 2010. Cubicin (daptomycin for injection) (full prescribing information). Cubist Pharmaceuticals, Lexington, MA.
8. Sarnak MJ, Jaber BL. 2000. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 58:1758-1764.
9. Tokars JI, Miller ER, Stein G. 2002. New national surveillance system for hemodialysis-associated infections: Initial results. Am. J. Infect. Control 30:288-295.
10. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. 2009. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 4:1190-1194.
11. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. 2010. Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol. Dial. Transplant. 25:1279-1284.
12. Benziger DP, Pertel PE, Donovan J, Yankelev S, Schwab RJ, Swan SK, Cannon C. 2011. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin. Nephrol. 75:63-69.
13. Patel N, Cardone K, Grabe DW, Meola S, Hoy C, Manley H, Drusano GL, Lodise TP. 2011. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrob. Agents Chemother. 55:1677-1683.
14. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. 2010. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568-1574.
15. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
16. Leary R, Jelliffe R, Schumitzky A, van Guilder M. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p 389-394. In Proc. Fourteenth IEEE Symp. Computer-Based Med. Syst. IEEE Computer Society, Bethesda, MD.
17. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: Pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA. 18. Bowker KE, Noel AR, MacGowan AP. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J. Antimicrob. Chemother. 64: 1044-1051.
18. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. 2003. Pharmacodynamic profile of daptomycin against Enterococcus spe-cies and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. 52:405-411.
19. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851.
20. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
21. Eisenstein BI, Oleson FB, Jr., Baltz RH. 2010. Daptomycin: From the mountain to the clinic, with essential help from Francis Tally, MD. Clin. Infect. Dis. 50(Suppl 1):S10-S15.
22. Oleson FB, Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. 2000. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother. 44:2948-2953.
23. Eyler RF, Mueller BA. 2010. Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. Adv. Chronic Kidney Dis. 17:392-403.
24. Heintz BH, Matzke GR, Dager WE. 2009. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29:562-577.
25. KDOQI, National Kidney Foundation. 2006. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 47:S11-S145.
26. McDowell MA, Fryar CD, Ogden CL, Flegal KM. 2008. Anthropometric reference data for children and adults: United States, 2003-2006. National health statistics reports, no. 10. National Center for Health Statistics, Hyattsville, MD.